Nuvation Bio Inc. (NUVB)
Largest Insider Buys in Sector
NUVB Stock Price History Chart
NUVB Stock Performance
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an …
Insider Activity of Nuvation Bio Inc.
Over the last 12 months, insiders at Nuvation Bio Inc. have bought $3.04M and sold $162,883 worth of Nuvation Bio Inc. stock.
On average, over the past 5 years, insiders at Nuvation Bio Inc. have bought $6.57M and sold $22.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cui Xiangmin (director) — $2.32M. BLICKENSTAFF KIM D (director) — $1.5M. Mashal Robert (director) — $220,000.
The last purchase of 100,000 shares for transaction amount of $220,000 was made by Mashal Robert (director) on 2024‑10‑08.
List of Insider Buy and Sell Transactions, Nuvation Bio Inc.
| 2024-11-11 | Sale | CEO, ANHEART THERAPEUTICS LTD. | 56,361 0.0161% | $2.89 | $162,883 | -10.30% | ||
| 2024-10-08 | director | 100,000 0.0359% | $2.20 | $220,000 | +8.97% | |||
| 2024-06-25 | director | 277,895 0.1098% | $2.97 | $825,348 | -5.76% | |||
| 2024-06-24 | director | 336,874 0.1354% | $2.98 | $1M | -4.33% | |||
| 2024-06-21 | director | 75,411 0.0321% | $3.00 | $226,233 | -5.74% | |||
| 2024-06-20 | director | 87,715 0.0372% | $2.99 | $262,268 | -4.95% | |||
| 2024-06-11 | director | 172,189 0.071% | $2.90 | $500,089 | +1.05% | |||
| 2023-09-21 | director | 53,000 0.0243% | $1.36 | $72,138 | +59.35% | |||
| 2023-09-20 | director | 117,100 0.0542% | $1.36 | $159,490 | +62.22% | |||
| 2023-09-19 | director | 5.14M 2.2462% | $1.26 | $6.46M | +64.39% | |||
| 2023-02-21 | director | 53,000 0.016% | $1.36 | $72,138 | -20.39% | |||
| 2023-02-20 | director | 117,100 0.0339% | $1.36 | $159,490 | -20.39% | |||
| 2023-02-19 | director | 5.14M 1.3737% | $1.26 | $6.46M | -20.39% | |||
| 2022-12-05 | director | 43,000 0.02% | $1.95 | $83,962 | -12.37% | |||
| 2022-12-02 | director | 47,000 0.0215% | $1.98 | $93,187 | -15.00% | |||
| 2022-12-01 | director | 84,959 0.0391% | $1.97 | $167,599 | -14.14% | |||
| 2022-11-30 | director | 75,041 0.0336% | $1.85 | $139,088 | -10.73% | |||
| 2022-04-05 | Sale | 2.5M 1.1241% | $5.60 | $14M | -59.30% | |||
| 2021-12-15 | Sale | 10 percent owner | 500,000 0.2537% | $10.07 | $5.04M | -64.26% | ||
| 2021-12-07 | Sale | 10 percent owner | 1.4M 0.726% | $9.80 | $13.72M | -61.57% |
Insider Historical Profitability
| Cui Xiangmin | director | 2453131 0.7289% | $2.74 | 4 | 0 | |
| BLICKENSTAFF KIM D | director | 172189 0.0512% | $2.74 | 1 | 0 | |
| Mashal Robert | director | 100000 0.0297% | $2.74 | 1 | 0 | |
| NODELMAN OLEG | director | 12674775 3.7659% | $2.74 | 12 | 2 | <0.0001% |
| EcoR1 Panacea Holdings, LLC | 390000 0.1159% | $2.74 | 1 | 0 |
Institutional Investor Ownership
| Fidelity Investments | $100.96M | 11.22 | 27.74M | +6.15% | +$5.85M | 0.01 | |
| Ecor1 Capital Llc | $69.92M | 7.77 | 19.21M | 0% | +$0 | 0.49 | |
| Omega Fund Management Llc | $51.22M | 5.69 | 14.07M | -6.63% | -$3.64M | 37.97 | |
| BlackRock | $45.61M | 5.07 | 12.53M | -2.74% | -$1.29M | <0.01 | |
| The Vanguard Group | $27.42M | 3.05 | 7.53M | +3% | +$799,100.13 | <0.01 |